Varicella Virus Vaccine Live (Varivax)
Varicella Virus Vaccine Live is an FDA-licensed reference biologic from Merck Sharp & Dohme LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
Varivax Varicella Virus Vaccine Live
Merck Sharp & Dohme LLC
- Approved
- Feb 27, 2023
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Varicella Virus Vaccine Live, in chronological order.
Reference approval
Approval date of the reference Varicella Virus Vaccine Live product.
3 yr 4 mo ago
Frequently asked questions
Are there biosimilars approved for Varicella Virus Vaccine Live (Varivax)?
No 351(k) biosimilars or interchangeable biosimilars referencing Varicella Virus Vaccine Live are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.